ライフサイエンスコーパス: biliary cirrhosis

1 itis (PBC, previously referred to as primary biliary cirrhosis).

2 liver inflammation similar to human primary biliary cirrhosis.

3 sponse in the dnTGF-betaRII model of primary biliary cirrhosis.

4 s of small bile duct injury found in primary biliary cirrhosis.

5 e models as well as in patients with primary biliary cirrhosis.

6 of relevance for the pathogenesis of primary biliary cirrhosis.

7 r disease, autoimmune hepatitis, and primary biliary cirrhosis.

8 t may break immunologic tolerance in primary biliary cirrhosis.

9 which are targets for destruction in primary biliary cirrhosis.

10 x (PDC)-E2, the major autoantigen of primary biliary cirrhosis.

11 is the immunodominant autoantigen of primary biliary cirrhosis.

12 leotide sequences from patients with primary biliary cirrhosis.

13 to suggest a viral association with primary biliary cirrhosis.

14 tified in about 95% of patients with primary biliary cirrhosis.

15 s to clarify the efficacy of UDCA in primary biliary cirrhosis.

16 s to clarify the efficacy of UDCA in primary biliary cirrhosis.

17 /or liver histology in patients with primary biliary cirrhosis.

18 ve inflammatory disease leading to secondary biliary cirrhosis.

19 improves transplant-free survival in primary biliary cirrhosis.

20 s, nonalcoholic steatohepatitis, and primary biliary cirrhosis.

21 tients had developed alcoholic and secondary biliary cirrhosis.

22 survival during chronic inflammation such as biliary cirrhosis.

23 ion and reduces eosinophil counts in primary biliary cirrhosis.

24 er disease, HIV/HCV co-infection and primary biliary cirrhosis.

25 primary pulmonary hypertension with primary biliary cirrhosis (1).

26 rhosis (1), hemochromatosis (1), and primary biliary cirrhosis (1).

27 ound in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with systemic

28 ere in seronegative hepatitis (17%), primary biliary cirrhosis (16%), and primary sclerosing cholangi

29 lanted for other indications such as primary biliary cirrhosis (8.2%; P<0.05), primary sclerosing cho

30 ble-blind study of 165 patients with primary biliary cirrhosis (95% women) and levels of alkaline pho

31 herapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic liver diseas

32 mutants for reactivities against 60 primary biliary cirrhosis and 103 control sera.

33 is markedly reduced in patients with primary biliary cirrhosis and biliary atresia or with Alagille s

34 lerosing cholangitis, in addition to primary biliary cirrhosis and biliary atresia.

35 anishing bile duct syndromes (VBDS), primary biliary cirrhosis and chronic allograft rejection, chola

36 osing lesion of the bile ducts that leads to biliary cirrhosis and is the most frequent indication fo

37 ween autoimmune liver diseases, with primary biliary cirrhosis and its antimitochondrial-negative var

38 sms, may precipitate autoimmunity in primary biliary cirrhosis and other autoimmune diseases.

39 In contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis wit

40 ammatory effects and to benefit both primary biliary cirrhosis and primary sclerosing cholangitis.

41 trahepatic cholestasis of pregnancy, primary biliary cirrhosis and primary sclerosing cholangitis.

42 surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholangitis.

43 Progression to biliary cirrhosis and the development of portal hyperten

44 patients with this entity to avoid secondary biliary cirrhosis and to eliminate the preventable need

45 hol-related), (2) cholestatic (e.g., primary biliary cirrhosis), and (3) cryptogenic.

46 hematosus (SLE), Sjogren's syndrome, primary biliary cirrhosis, and active hepatitis.

47 ients with hepatitis C, hepatitis B, primary biliary cirrhosis, and autoimmune hepatitis.

48 also influence autoimmune hepatitis, primary biliary cirrhosis, and cholangiocarcinogenesis.

49 te/nitrate levels were elevated in rats with biliary cirrhosis, and decreased after administration of

50 with time, leading to recurrent cholangitis, biliary cirrhosis, and end-stage liver disease.

51 iary atresia, hepatitis BC, alcohol, primary biliary cirrhosis, and fulminant hepatitis.

52 sion showed that younger recipients, primary biliary cirrhosis, and previous graft loss were independ

53 orders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.

54 trahepatic cholestasis of pregnancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

55 into the pathogenesis of gallstones, primary biliary cirrhosis, and primary sclerosing cholangitis.

56 hyperdynamic circulation in the rat model of biliary cirrhosis, and that this is associated with decr

57 ing prognosis in biliary atresia and primary biliary cirrhosis; and important clinical trials in intr

58 (AMAs), the serological hallmark of primary biliary cirrhosis, are directed against the lipoyl domai

59 primary sclerosing cholangitis, and primary biliary cirrhosis as a group had a tendency toward CM st

60 ) is the only approved treatment for primary biliary cirrhosis, but its effect on disease progression

61 ) is the only approved treatment for primary biliary cirrhosis, but its effect on disease progression

62 g primary sclerosing cholangitis and primary biliary cirrhosis, but not with single-nucleotide polymo

63 hemical test results and symptoms in primary biliary cirrhosis, but the response to methotrexate was

64 node homogenates from patients with primary biliary cirrhosis can induce autoantigen expression in n

65 biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death d

66 ed formation of reactive nitrogen species in biliary cirrhosis causes nitration of cardiac proteins a

67 ay a key role in the pathogenesis of primary biliary cirrhosis, cholangiocarcinoma, liver cysts, and

68 hemochromatosis, Wilson's disease) and ICC (biliary cirrhosis, cholangitis, cholelithiasis, choledoc

69 %). patients with portal vein thrombosis and biliary cirrhosis demonstrated better survival than othe

70 panning haplotype is associated with primary biliary cirrhosis, demonstrating the nuance of similarit

71 Patients with primary biliary cirrhosis develop progressive ductopenia associa

72 pathogenesis, and natural history of primary biliary cirrhosis, discuss management of the disease and

73 a, alcohol cirrhosis, hepatitis C or primary biliary cirrhosis, donor age 40 years or younger, or les

74 clinical features, and treatment of primary biliary cirrhosis, drug-induced cholestasis, and cholest

75 iduals with autoimmune hepatitis and primary biliary cirrhosis entered remission during corticosteroi

76 understanding of the pathogenesis of primary biliary cirrhosis, familial intrahepatic cholestasis, bi

77 cholangitis, cellular rejection, and primary biliary cirrhosis, four liver diseases affecting cholang

78 Primary biliary cirrhosis frequently progresses despite treatmen

79 The typical course of primary biliary cirrhosis has changed substantially with the int

80 of a bacterial role in the cause of primary biliary cirrhosis has received recent attention, based o

81 d that the majority of patients with primary biliary cirrhosis have both RT-PCR and immunohistochemis

82 Here we show that rats with biliary cirrhosis have low blood pressure, which is elev

83 s, alcoholic liver disease, liver cirrhosis, biliary cirrhosis, hemochromatosis, Wilson's disease) an

84 ASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluore

85 ldren causes progressive fibrosis leading to biliary cirrhosis; however, its cause(s) and early patho

86 une cholangitis with similarities to primary biliary cirrhosis in humans.

87 ately predict the natural history of primary biliary cirrhosis in individuals.

88 clerosing cholangitis, and recurrent primary biliary cirrhosis in terms of the clinical entity, the s

89 rd of those previously described for primary biliary cirrhosis in the same population.

90 s found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with systemic

91 esis was investigated in rats with secondary biliary cirrhosis induced by bile duct ligation (BDL) fo

92 s the role of p38alpha in the progression of biliary cirrhosis induced by chronic cholestasis as an e

93 increase the severity of autoimmune primary biliary cirrhosis induced by infection with Novosphingob

94 ycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and other c

95 Primary biliary cirrhosis is a chronic cholestatic liver disease

96 Primary biliary cirrhosis is a chronic cholestatic liver disease

97 Primary biliary cirrhosis is a chronic inflammatory disease of t

98 Primary biliary cirrhosis is an immune-mediated chronic liver di

99 esis of the autoimmune liver disease primary biliary cirrhosis is breakdown of T-cell self-tolerance

100 Identification of primary biliary cirrhosis is important, because effective treatm

101 The serological hallmark of primary biliary cirrhosis is the antimitochondrial antibody, a h

102 uding exocrine pancreatic destruction, focal biliary cirrhosis, micro-gallbladder, vas deferens loss,

103 (n = 10), and disease controls with primary biliary cirrhosis (n = 10).

104 65 patients with hepatocellular (n = 31) or biliary cirrhosis (n = 34).

105 for recurrence of original disease: primary biliary cirrhosis (n= 19), sclerosing cholangitis (n=6),

106 n serum samples of disease controls (primary biliary cirrhosis; n = 22).

107 epatic cholestasis of pregnancy, and primary biliary cirrhosis; new information for assessing prognos

108 antly higher than from patients with primary biliary cirrhosis or nonalcoholic steatohepatitis (P < .

109 resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic steatohepatitis, and c

110 with alcohol-induced liver disease, primary biliary cirrhosis, or chronic hepatitis C.

111 e hepatitis (P = 0.01, HR = 4.2) and primary biliary cirrhosis (P = 0.04, HR = 2).

112 an established mouse model of decompensated biliary cirrhosis, p21-deficient mice, and liver tissue

113 f primary sclerosing cholangitis and primary biliary cirrhosis patient liver samples.

114 langiocytes from control patients or primary biliary cirrhosis patients nor in hepatocytes from any o

115 Compared to healthy controls or primary biliary cirrhosis patients, PBMCs from PSC patients mani

116 patients with cirrhosis secondary to primary biliary cirrhosis (PBC) (n = 6), and (4) healthy control

117 w-up and only included patients with primary biliary cirrhosis (PBC) according to established diagnos

118 w-up and only included patients with primary biliary cirrhosis (PBC) according to established diagnos

119 antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ur

120 are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before the onset

121 d protein expression in the liver of primary biliary cirrhosis (PBC) and controls.

122 sons were made between patients with primary biliary cirrhosis (PBC) and hepatocellular cirrhosis (HC

123 temporal changes in the incidence of primary biliary cirrhosis (PBC) and investigated associations be

124 ked as a strong component underlying primary biliary cirrhosis (PBC) and other autoimmune disorders.

125 holestatic liver diseases, including primary biliary cirrhosis (PBC) and primary sclerosing cholangit

126 Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangit

127 ts who underwent transplantation for primary biliary cirrhosis (PBC) and primary sclerosing cholangit

128 Primary biliary cirrhosis (PBC) and primary sclerosing cholangit

129 0 consecutive patients with advanced primary biliary cirrhosis (PBC) and primary sclerosing cholangit

130 was administered in 96 patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangit

131 among 447 transplant recipients with primary biliary cirrhosis (PBC) and primary sclerosing cholangit

132 Primary biliary cirrhosis (PBC) and primary sclerosing cholangit

133 oantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtu

134 Sera from patients with primary biliary cirrhosis (PBC) are characterized by the presenc

135 nsplantation for classical end-stage primary biliary cirrhosis (PBC) are described, who went on to de

136 utoreactive T-cell responses seen in primary biliary cirrhosis (PBC) are typically of the Th1 phenoty

137 tudy we showed that in patients with primary biliary cirrhosis (PBC) being positive or negative for a

138 efficacy of liver transplantation in primary biliary cirrhosis (PBC) by demonstrating that the actual

139 They were distinguished from primary biliary cirrhosis (PBC) by higher serum levels of AST an

140 Patients with primary biliary cirrhosis (PBC) characteristically show circulat

141 PSC and LTx cohort patients and primary biliary cirrhosis (PBC) control patients were genotyped

142 liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized,

143 ntry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, double

144 e studies suggest that patients with primary biliary cirrhosis (PBC) experience significant problems

145 cholestatic liver diseases including primary biliary cirrhosis (PBC) for which it has a positive effe

146 Patients with primary biliary cirrhosis (PBC) frequently experience significan

147 We genotyped 2,861 cases of primary biliary cirrhosis (PBC) from the UK PBC Consortium and 8

148 Primary biliary cirrhosis (PBC) has a complex clinical phenotype

149 iation between cigarette smoking and primary biliary cirrhosis (PBC) has been demonstrated.

150 Our understanding of primary biliary cirrhosis (PBC) has been significantly enhanced

151 ike other autoimmune liver diseases, primary biliary cirrhosis (PBC) has never been reported in early

152 The epidemiology of primary biliary cirrhosis (PBC) has not been studied systematica

153 rsy exists as to whether people with primary biliary cirrhosis (PBC) have an increased risk of develo

154 locus, six genetic risk factors for primary biliary cirrhosis (PBC) have been identified in recent g

155 Patients with primary biliary cirrhosis (PBC) have both serologic and tissue e

156 Primary biliary cirrhosis (PBC) illustrates this paradigm becaus

157 Primary biliary cirrhosis (PBC) is a chronic cholestatic liver d

158 Primary biliary cirrhosis (PBC) is a chronic cholestatic liver d

159 Primary biliary cirrhosis (PBC) is a chronic, cholestatic diseas

160 Primary biliary cirrhosis (PBC) is a classical autoimmune liver

161 Primary biliary cirrhosis (PBC) is a disease of unknown etiology

162 Primary biliary cirrhosis (PBC) is a disease with genetic and en

163 Primary biliary cirrhosis (PBC) is a liver disease characterized

164 Primary biliary cirrhosis (PBC) is a progressive autoimmune live

165 Primary biliary cirrhosis (PBC) is a progressive cholestatic liv

166 Primary biliary cirrhosis (PBC) is an autoimmune disease charact

167 Primary biliary cirrhosis (PBC) is an autoimmune disease of the

168 Primary biliary cirrhosis (PBC) is an autoimmune disease of unkn

169 Primary biliary cirrhosis (PBC) is an autoimmune disease with a

170 Primary biliary cirrhosis (PBC) is an autoimmune liver disease c

171 Primary biliary cirrhosis (PBC) is an organ-specific autoimmune

172 Primary biliary cirrhosis (PBC) is an uncommon chronic cholestat

173 Primary biliary cirrhosis (PBC) is characterized by an intense b

174 Primary biliary cirrhosis (PBC) is characterized by antimitochon

175 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by autoreactive

176 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by the breakdow

177 Primary biliary cirrhosis (PBC) is considered a model autoimmune

178 Primary biliary cirrhosis (PBC) is considered a model autoimmune

179 chondrial antibody (AMA) response in primary biliary cirrhosis (PBC) is directed against the E2 compo

180 The etiology of primary biliary cirrhosis (PBC) is far from clear.

181 Primary biliary cirrhosis (PBC) is generally a slowly progressiv

182 ts with the autoimmune liver disease primary biliary cirrhosis (PBC) is increasing, although its inci

183 lopment of liver fibrosis markers in primary biliary cirrhosis (PBC) is needed to facilitate the asse

184 Primary biliary cirrhosis (PBC) is often considered to be a dry

185 Primary biliary cirrhosis (PBC) is sometimes diagnosed based on

186 The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly directed and

187 stic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer an

188 The serological hallmark of primary biliary cirrhosis (PBC) is the presence of pyruvate dehy

189 A major enigma of primary biliary cirrhosis (PBC) is the selective targeting of bi

190 The cause of primary biliary cirrhosis (PBC) is unclear.

191 biquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained.

192 though the etiology and mechanism of primary biliary cirrhosis (PBC) is unknown, growing evidence sug

193 Patients with primary biliary cirrhosis (PBC) may be at increased risk for mal

194 %, autoimmune hepatitis in 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing cholangiti

195 therapy for patients with end-stage primary biliary cirrhosis (PBC) or primary sclerosing cholangiti

196 More than 95% of primary biliary cirrhosis (PBC) patients have detectable levels

197 BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have been per

198 ear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly higher lev

199 Primary biliary cirrhosis (PBC) recurs in the allograft after li

200 for organ-specific tissue damage in primary biliary cirrhosis (PBC) remain an enigma, it has been su

201 Although the etiology of primary biliary cirrhosis (PBC) remains unknown, environmental f

202 the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.

203 Autoimmune diseases such as primary biliary cirrhosis (PBC) result from failure in the immun

204 nificant proportion of patients with primary biliary cirrhosis (PBC) suffer from severe fatigue.

205 th humans and murine models of human primary biliary cirrhosis (PBC) suggest that activated T cells,

206 The incidence of primary biliary cirrhosis (PBC) varies widely between regions.

207 Primary biliary cirrhosis (PBC) was first described in the 1950s

208 The treatment of primary biliary cirrhosis (PBC) with conventional immunosuppress

209 were collected from 91 patients with primary biliary cirrhosis (PBC), 28 immediate relatives, and 41

210 Primary biliary cirrhosis (PBC), a chronic autoimmune liver dise

211 estatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected patients fro

212 iary epithelial cells from explanted primary biliary cirrhosis (PBC), and control liver using a total

213 steatohepatitis (NASH), hepatitis B, primary biliary cirrhosis (PBC), and primary sclerosing cholangi

214 dence of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangi

215 patients who subsequently developed primary biliary cirrhosis (PBC), and thus may be involved in its

216 dical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show an incom

217 duct epithelium during the course of primary biliary cirrhosis (PBC), but the importance of ICAM-1 an

218 found in the livers of subjects with primary biliary cirrhosis (PBC), but the mechanisms involved rem

219 sometimes exhibited in patients with primary biliary cirrhosis (PBC), but the postulated autoimmune m

220 The immunodominant autoantigen in primary biliary cirrhosis (PBC), E2 components of pyruvate dehyd

221 nophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early stages.

222 ion of biliary epithelia observed in primary biliary cirrhosis (PBC), graft-versus-host disease (GVHD

223 une cholangitis that resembles human primary biliary cirrhosis (PBC), including antimitochondrial ant

224 we show that SNPs conferring risk to primary biliary cirrhosis (PBC), inflammatory bowel disease (IBD

225 In primary biliary cirrhosis (PBC), it has been postulated that hal

226 In primary biliary cirrhosis (PBC), patients develop a multilineage

227 the nonviral chronic liver diseases primary biliary cirrhosis (PBC), primary sclerosing cholangitis

228 The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial response

229 In primary biliary cirrhosis (PBC), the major autoepitope recognize

230 um of more than 95% of patients with primary biliary cirrhosis (PBC), the major epitope being the inn

231 er characterize the genetic basis of primary biliary cirrhosis (PBC), we genotyped 2426 PBC patients

232 une biliary disease (ABD) resembling primary biliary cirrhosis (PBC).

233 y influence complex diseases such as primary biliary cirrhosis (PBC).

234 dies (AMAs) closely resembling human primary biliary cirrhosis (PBC).

235 rosing cholangitis (PSC), but seldom primary biliary cirrhosis (PBC).

236 ognition and epitope modification in primary biliary cirrhosis (PBC).

237 increased frequency in patients with primary biliary cirrhosis (PBC).

238 in the response to biliary injury in primary biliary cirrhosis (PBC).

239 d several clinical manifestations of primary biliary cirrhosis (PBC).

240 s a significant genetic component to primary biliary cirrhosis (PBC).

241 e elevated in all indications except primary biliary cirrhosis (PBC).

242 ies, has been extensively studied in primary biliary cirrhosis (PBC).

243 sative agents in the pathogenesis of primary biliary cirrhosis (PBC).

244 ary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC).

245 is a well-recognized complication of primary biliary cirrhosis (PBC).

246 UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC).

247 ognized as a serological hallmark of primary biliary cirrhosis (PBC).

248 y and environmental factors leads to primary biliary cirrhosis (PBC).

249 se mammary tumor virus (MMTV) causes primary biliary cirrhosis (PBC).

250 ed by antimitochondrial Abs (AMA) in primary biliary cirrhosis (PBC).

251 proposed as immunologic triggers for primary biliary cirrhosis (PBC).

252 ved in generation of autoepitopes in primary biliary cirrhosis (PBC).

253 T lymphocytes in the pathogenesis of primary biliary cirrhosis (PBC).

254 iver from controls and patients with primary biliary cirrhosis (PBC).

255 that characterizes diseases such as primary biliary cirrhosis (PBC).

256 dical therapy for most patients with primary biliary cirrhosis (PBC).

257 treatment for patients with advanced primary biliary cirrhosis (PBC).

258 orresponding to the ducts damaged in primary biliary cirrhosis (PBC).

259 rtant criterion for the diagnosis of primary biliary cirrhosis (PBC).

260 ed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

261 ociated with the etiopathogenesis of primary biliary cirrhosis (PBC).

262 (SIR 2.78); five of these cases had primary biliary cirrhosis (PBC).

263 pposing effects on susceptibility to primary biliary cirrhosis (PBC).

264 isease that strongly resembles human primary biliary cirrhosis (PBC).

265 s is a complication in patients with primary biliary cirrhosis (PBC).

266 r biopsy is important for diagnosing primary biliary cirrhosis (PBC).

267 ribed with features similar to human primary biliary cirrhosis (PBC).

268 mononuclear cells from patients with primary biliary cirrhosis (PBC).

269 es, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholan

270 ed for adults receiving first LT for primary biliary cirrhosis (PBC; n=3052), primary sclerosing chol

271 m biliary causes of cirrhosis (e.g., primary biliary cirrhosis [PBC], and primary sclerosing cholangi

272 ated with the development of oxidant injury, biliary cirrhosis, portal hypertension, and a hyperdynam

273 Primary biliary cirrhosis, primary sclerosing cholangitis and bi

274 and clinical trials of therapies for primary biliary cirrhosis, primary sclerosing cholangitis and in

275 VCAM-1 was detected on BDs in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoh

276 re Laennec's cirrhosis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, and c

277 Additionally, the diagnoses of primary biliary cirrhosis, primary sclerosing cholangitis, autoi

278 ific cholestatic syndromes including primary biliary cirrhosis, primary sclerosing cholangitis, bilia

279 clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, chole

280 clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, chole

281 itus due to liver disease (including primary biliary cirrhosis, primary sclerosing cholangitis, chron

282 tis C with hepatocellular carcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, ethan

283 h cholestatic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, intra

284 ried for deceased donor first LT for primary biliary cirrhosis, primary sclerosing cholangitis, or al

285 The precise aetiopathogenesis of primary biliary cirrhosis remains unknown, although dysregulatio

286 , exocrine pancreatic destruction, and focal biliary cirrhosis, replicating abnormalities seen in new

287 Crohn's disease, Addison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idiopa

288 Recurrent primary biliary cirrhosis (RPBC) is a histologic diagnosis.

289 including scleroderma, thyroiditis, primary biliary cirrhosis, Sjogren syndrome, systemic lupus, der

290 ccur in the pancreas (malabsorption), liver (biliary cirrhosis), sweat glands (heat shock), and vas d

291 lly relevant problem is progression of focal biliary cirrhosis to multilobular cirrhosis with its att

292 Secondary biliary cirrhosis was induced in rats by bile duct ligat

293 the role of B cells in this model of primary biliary cirrhosis, we bred B cell-deficient mice (Igmu(-

294 elop the phenotypic manifestation of primary biliary cirrhosis when cocultivated in serial passage wi

295 es to breakdown of self-tolerance in primary biliary cirrhosis, whereas those of DR1101 promote toler

296 ed controlled trial of patients with primary biliary cirrhosis who had an inadequate response to urso

297 pared with placebo, in patients with primary biliary cirrhosis who had inadequate responses to ursode

298 tients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphatase (ALP)

299 tients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphatase level

300 for autoreactive immune responses in primary biliary cirrhosis, with lipoic acid itself forming a com